Kanyin E. Zhang is a Non-Executive Director of Aranda Pharma Ltd. Kanyin has more than 20 years of experience in drug discovery and development from both US and China. Kanyin began his pharmaceutical research career in the US and held various positions from Research Scientist to Director of DMPK/Pharmacology at Merck, Agouron/Pfizer and GNF (Genomics Institute of the Novartis Research Foundation), and he has been involved in the development of two marketed products and a dozen clinical candidates. After returning to China, he joined Argusina Biosciences, a drug discovery startup founded by Morningside, as a founding member, vice president and general manager at its Shanghai R&D center. Kanyin received his Ph.D. degree from the School of Pharmacy at the University of Washington, Seattle. Currently Kanyin serves as founding CEO of Tarrex Biopharma Ltd, a Chinese drug discovery company developing anti-cancer therapeutics. Kanyin E. Zhang is a Non-Executive Director of Aranda Pharma Ltd. Kanyin has more than 20 years of experience in drug discovery and development from both US and China. Kanyin began his pharmaceutical research career in the US and held various positions from Research Scientist to Director of DMPK/Pharmacology at Merck, Agouron/Pfizer and GNF (Genomics Institute of the Novartis Research Foundation), and he has been involved in the development of two marketed products and a dozen clinical candidates. After returning to China, he joined Argusina Biosciences, a drug discovery startup founded by Morningside, as a founding member, vice president and general manager at its Shanghai R&D center. Kanyin received his Ph.D. degree from the School of Pharmacy at the University of Washington, Seattle. Currently Kanyin serves as founding CEO of Tarrex Biopharma Ltd, a Chinese drug discovery company developing anti-cancer therapeutics.

Pharmaceutical industry